Managing adverse effects and drug-drug interactions of antiplatelet agents

Nature Reviews Cardiology

Volumn 8, Issue 10, 2011, Pages 592-600

  Kalyanasundaram, Arun ^a   Lincoff, A Michael ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTITHROMBOCYTIC AGENT; APROTININ; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DESMOPRESSIN; EPTIFIBATIDE; FAMOTIDINE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; METOPROLOL; OMEPRAZOLE; PRASUGREL; PROTAMINE; PROTON PUMP INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; TRANEXAMIC ACID; WARFARIN;

ACUTE CORONARY SYNDROME; BRAIN HEMORRHAGE; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEMOSTASIS; HUMAN; INCIDENCE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

AGE FACTORS; AGED; AGED, 80 AND OVER; DRUG INTERACTIONS; DYSPNEA; HEMATOLOGIC DISEASES; HEMORRHAGE; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYPHARMACY; RISK ASSESSMENT; RISK FACTORS;

EID: 80053226951     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.128     Document Type: Review

References (93)

1. Bennett, C. L. et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N. Engl. J. Med. 342, 1773-1777 (2000). (Pubitemid 30390236)
2. Jakubowski, J. A. et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc. Drug Rev. 25, 357-374 (2007). (Pubitemid 350233359)
3. Bhatt, D. L. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N. Engl. J. Med. 357, 2078-2081 (2007). (Pubitemid 350106717)
4. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
5. Capodanno, D., Dharmashankar, K. & Angiolillo, D. J. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev. Cardiovasc. Ther. 8, 151-158 (2010).
6. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
7. Meadows, T. A. & Bhatt, D. L. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. 100, 1261-1275 (2007). (Pubitemid 46742917)
8. Alli, O. et al. Incidence, predictors, and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel. J. Clin. Gastroenterol. 45, 410-414 (2011).
9. Mehta, S. R. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001). (Pubitemid 32772726)
10. Kapetanakis, E. I. et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur. Heart. J. 26, 576-583 (2005). (Pubitemid 40461099)
11. Kapetanakis, E. I. et al. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation 113, 1667-1674 (2006).
12. Kastrati, A. et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 350, 232-238 (2004). (Pubitemid 38071801)
13. Husted, S. Benefits and risks with antiplatelet therapy: how great a problem is bleeding? Eur. Heart J. 10 (Suppl. I), I19-I24 (2008).
14. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348, 1329-1339 (1996).
15. Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N. Engl. J. Med. 345, 494-502 (2001). (Pubitemid 32758501)
16. Chen, Z. M. et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005).
17. Trimarchi, S. et al. Retroperitoneal hematoma after percutaneous coronary intervention: prevalence, risk factors, management, outcomes, and predictors of mortality. J. Am. Coll. Cardiol. Interv. 3, 845-850 (2010).
18. Farouque, H. M. et al. Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices. J. Am. Coll. Cardiol. 45, 363-368 (2005). (Pubitemid 40186785)
19. Serebruany, V. L. et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am. J. Cardiol. 95, 1218-1222 (2005). (Pubitemid 40616424)
20. Mehta, S. R. et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376, 1233-1243 (2010).
21. Bhatt, D. L. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
22. Sabatine, M. S. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST segment elevation. N. Engl. J. Med. 352, 1179-1189 (2005). (Pubitemid 40397259)
23. Cannon, C. P. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375, 283-293 (2010).
24. Winchester, D. E. et al. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J. Am. Coll. Cardiol. 57, 1190-1199 (2011).
25. Marso, S. P. et al. Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. JAMA 303, 2156-2164 (2010).
26. Rao, S. V. et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc. Interv. 1, 379-386 (2008).
27. Aguirre, F. V. & Gill, J. B. Increasing benefit, reducing risk: focusing on hemorrhagic complications in percutaneous coronary intervention. J. Invasive Cardiol. 14 (Suppl. B), 48B-54B (2002). (Pubitemid 34308466)
28. Alexander, K. P. et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non ST segment elevation acute coronary syndromes. JAMA 294, 3108-3116 (2005). (Pubitemid 43016802)
29. Peters, R. J. et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 108, 1682-1687 (2003). (Pubitemid 37243654)
30. Yang, X. et al. The implications of blood transfusions for patients with non ST segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J. Am. Coll. Cardiol. 46, 1490-1495 (2005). (Pubitemid 41446184)
31. Buresly, K., Eisenberg, M. J., Zhang, X. & Pilote, L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch. Intern. Med. 165, 784-789 (2005). (Pubitemid 40569432)
32. Konstantino, Y. et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 105, 80-85 (2006). (Pubitemid 43189779)
33. Lincoff, A. M. et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. Am. J. Cardiol. 79, 286-291 (1997). (Pubitemid 27093302)
34. Fox, K. A. et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non ST elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110, 1202-1208 (2004). (Pubitemid 39202333)
35. Cannon, C. P., Mehta, S. R. & Aranki, S. F. Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. Ann. Thorac. Surg. 80, 768-779 (2005). (Pubitemid 41019536)
36. Chin, M. W., Yong, G., Bulsara, M. K., Rankin, J. & Forbes G. M. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am. J. Gastroenterol. 102, 2411-2416 (2007). (Pubitemid 47631776)
37. Foley, P., Foley, S., Kinnaird, T. & Anderson, R. A. Clinical review: gastrointestinal bleeding after percutaneous coronary intervention: a deadly combination. QJM 101, 425-433 (2008). (Pubitemid 351791525)
38. Tan, V. P., Yan, B. P., Kiernan, T. J. & Ajani, A. E. Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. Cardiovasc. Revasc. Med. 10, 36-44 (2009).
39. Patrono, C. Antiplatelet strategies. Eur. Heart J. 4, A42-A7 (2002).
40. Nácul, F. E., de Moraes, E., Penido, C., Paiva, R. B. & Méier-Neto, J. G. Massive nasal bleeding and hemodynamic instability associated with clopidogrel. Pharm. World Sci. 26, 6-7 (2004). (Pubitemid 38250172)
41. van der Linden, J., Lindvall, G. & Sartipy, U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation 112 (Suppl. 9), I276-I280 (2005). (Pubitemid 41266687)
42. von Heymann, C. et al. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates? Heart Surg. Forum 8, E39-E41 (2005). (Pubitemid 44795274)
43. Tcheng, J. E. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am. Heart J. 139, S38-S45 (2000). (Pubitemid 30091780)
44. US Food and Drug Adminisitration. Abciximab (ReoPro®) product label [online]. http://www.accessdata.fda.gov/drugsatfda-docs/label/1997/ abcicen110597-lab.pdf (1997).
45. Mascelli, M. A. et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 97, 1680-1688 (1998). (Pubitemid 28211416)
46. Kereiakes, D. J., Broderick, T. M., Whang, D. D., Anderson, L. & Fye, D. Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention. Am. J. Cardiol. 80, 633-634 (1997). (Pubitemid 27386153)
47. Leon, M. B. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 339, 1665-1671 (1998). (Pubitemid 28550691)
48. Berger, P. B. Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement? Curr. Control. Trials Cardiovasc. Med. 1, 83-87 (2000). (Pubitemid 32219884)
49. Steinhubl, S. R., Tan, W. A., Foody, J. M. & Topol, E. J. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 281, 806-810 (1999). (Pubitemid 29113740)
50. Dailymed Current Medication Information. Prasugrel prescribing information [online]. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id= 40172#s14 (2010).
51. Brieger, D. B., Mak, K. H., Kottke-Marchant, K. & Topol, E. J. Heparin-induced thrombocytopenia. J. Am. Coll. Cardiol. 31, 1449-1459 (1998). (Pubitemid 28273284)
52. Dasgupta, H. et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am. Heart J. 140, 206-211 (2000). (Pubitemid 30641579)
53. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 96, 1445-1453 (1997).
54. Berkowitz, S. D., Harrington, R. A., Rund, M. M. & Tcheng, J. E. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 95, 809-813 (1997). (Pubitemid 27091518)
55. Dasgupta, H. et al. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis. Am. Heart J. 140, 206-211 (2000). (Pubitemid 30641579)
56. Serebruany, V., Pokov, I., Kuliczkowski, W., Vahabi, J. & Atar, D. Incidence and causes of new-onset dyspnea in 3719 patients treated with clopidogrel and aspirin combination after coronary stenting. Thromb. Haemost. 100, 314-318 (2008).
57. Storey, R. F. et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J. Am. Coll. Cardiol. 56, 185-193 (2010).
58. US Food and Drug Adminisitration. Clopidogrel bisulfate (Plavix®) safety labeling changes [online]. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm225843htm (2011).
59. Wiviott, S. D. et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 116, 2923-2932 (2007).
60. Bhatt, D. L. et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363, 1909-1917 (2010).
61. O'Donoghue M. L. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374, 989-997 (2009).
62. Abraham, N. S. et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am. J. Gastroenterol. 105, 2533-2549 (2010).
63. US National Library of Medicine. ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT00930670 (2009).
64. Siller-Matula, J. M., Lang, I., Christ, G. & Jilma, B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J. Am. Coll. Cardiol. 52, 1557-1563 (2008).
65. Gremmel, T. et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 96, 186-189 (2010).
66. Olesen, J. B. et al. Calcium-channel blockers do not alter the clinical efficacy of clopidogrel after myocardial infarction: a nationwide cohort study. J. Am. Coll. Cardiol. 57, 409-417 (2011).
67. Lau, W. C. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107, 32-37 (2003). (Pubitemid 36070929)
68. Neubauer, H. Günesdogan, B., Hanefeld, C., Spiecker, M. & Mügge, A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function-a flow cytometry study. Eur. Heart J. 24, 1744-1749 (2003). (Pubitemid 37236863)
69. Serebruany, V. L. et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch. Intern. Med. 164, 2051-2057 (2004). (Pubitemid 39390564)
70. Geisler, T. et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur. Heart J. 29, 1635-1643 (2008). (Pubitemid 351957543)
71. Gorchakova, O. et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur. Heart J. 25, 1898-1902 (2004). (Pubitemid 39452606)
72. Mitsios, J. V., Papathanasiou, A. I., Elisaf, M., Goudevenos, J. A. & Tselepis, A. D. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets 16, 287-292 (2005). (Pubitemid 40943923)
73. Mitsios, J. V. et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109, 1335-1338 (2004). (Pubitemid 38387816)
74. Hirsh, J. et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107, 1692-1711 (2003). (Pubitemid 36397341)
75. Liu, A. Warfarin-drug interactions among older adults. Geriatr. Aging 10, 643-646 (2007). (Pubitemid 350252895)
76. Hansen, M. L. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch. Intern. Med. 170, 1433-1441 (2010).
77. US Food and Drug Adminisitration. Information for healthcare professionals: concomitant use of ibuprofen and aspirin [online]. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm125222htm (2006).
78. Hinz, B., Renner, B. & Brune, K. Drug insight: cyclo-oxygenase-2 inhibitors-a critical appraisal. Nat. Clin. Pract. Rheumatol. 3, 552-560 (2007). (Pubitemid 47506013)
79. Taha, A. S., McCloskey, C., Prasad, R. & Bezlyak, V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374, 119-125 (2009).
80. Ng, F. H. et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Gastroenterology 138, 82-88 (2010).
81. Lanas, A. et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 102, 507-515 (2007). (Pubitemid 46328156)
82. Braunwald, E. et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non ST segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol. 40, 1366-1374 (2002).
83. Caughey, G. E., Vitry, A. I., Gilbert, A. L. & Roughead, E. E. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health 8, 221 (2008).
84. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
85. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308, 81-106 (1994).
86. US National Library of Medicine. ClinicalTrials.gov [online]. http://clinicaltrials.gov/ct2/show/NCT01107912 (2011).
87. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N. Engl. J. Med. 339, 436-443 (1998).
88. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. 338, 1488-1497 (1998).
89. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N. Engl. J. Med. 338, 1498-1505 (1998).
90. Boersma, E. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359, 189-198 (2002). (Pubitemid 34113814)
91. Moscucci, M. et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur. Heart. J. 24, 1815-1823 (2003). (Pubitemid 37280247)
92. Kalyanasundaram, A. et al. Correlates of bleeding after a 600 mg loading dose of clopidogrel, with and without abciximab: a pooled analysis of 4 ISAR randomized trials [abstract]. Circulation 116, II-416 (2007).
93. Feit, F. et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE 2 trial. Am. J. Cardiol. 100, 1364-1369 (2007). (Pubitemid 47576015)